Condition: Moderate Aortic Valve Stenosis · Sponsor: Kardigan, Inc.
The purpose of this study is to evaluate if ataciguat slows the progression of moderate calcific aortic valve stenosis in adults.
This description comes directly from the study's public registry record.
Kardigan Clinical Trial Information Team · 1-877-310-5135 · clinicaltrials@kardigan.bio
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham (UAB) - Medical Center | Birmingham, Alabama, United States | Recruiting |
| Heart Center Research LLC | Huntsville, Alabama, United States | Recruiting |
| Mayo Clinic - Phoenix | Phoenix, Arizona, United States | Not Yet Recruiting |
| National Heart Institute | Beverly Hills, California, United States | Recruiting |
| UCLA Ronald Reagan Medical Center | Los Angeles, California, United States | Not Yet Recruiting |
| Hoag Memorial Hospital Presbyterian | Newport Beach, California, United States | Recruiting |
| Profound Research LLC at Southern California Heart Specialists | Pasadena, California, United States | Recruiting |
| University of California, San Francisco (UCSF) - Medical Center | San Francisco, California, United States | Recruiting |
| Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center | Torrance, California, United States | Recruiting |
| HCA Florida - JFK Hospital | Atlantis, Florida, United States | Recruiting |
| New Generation of Medical Research | Hialeah, Florida, United States | Recruiting |
| Memorial Healthcare System | Hollywood, Florida, United States | Not Yet Recruiting |
+ 62 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07001800